Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia

Front Cell Infect Microbiol. 2017 May 4:7:156. doi: 10.3389/fcimb.2017.00156. eCollection 2017.

Abstract

Infections caused by Acinetobacter baumannii (AB), an increasingly prevalent nosocomial pathogen, have been associated with high morbidity and mortality. We conducted this study to analyze the clinical features, outcomes, and factors influencing the survival of patients with AB bacteremia. We retrospectively examined the medical records of all patients developing AB bacteremia during their hospital stay at a tertiary care hospital in Beirut between 2010 and 2015. Ninety episodes of AB bacteremia were documented in eighty-five patients. Univariate analysis showed that prior exposure to high dose steroids, diabetes mellitus, mechanical ventilation, prior use of colistin and tigecycline, presence of septic shock, and critical care unit stay were associated with a poor outcome. High dose steroids and presence of septic shock were significant on multivariate analysis. Crude mortality rate was 63.5%. 70.3% of the deaths were attributed to the bacteremia. On acquisition, 39 patients had septicemia. Despite high index of suspicion and initiation of colistin and/or tigecycline in 18/39 patients, a grim outcome could not be averted and 37 patients died within 2.16 days. Seven patients had transient benign bacteremia; three of which were treated with removal of the line. The remaining four did not receive any antibiotics due to withdrawal of care and died within 26.25 days of acquiring the bacteremia, with no signs of persistent infection on follow up. A prolonged hospital stay is frequently associated with loss of functionality, and steroid and antibiotic exposure. These factors seem to impact the mortality of AB bacteremia, a disease with high mortality rate and limited therapeutic options.

Keywords: Acinetobacter baumannii; bacteremia; extensive drug resistance; outcome; risk factors; sepsis.

MeSH terms

  • Acinetobacter Infections / blood*
  • Acinetobacter Infections / drug therapy
  • Acinetobacter Infections / microbiology*
  • Acinetobacter Infections / physiopathology
  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / pathogenicity*
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / microbiology*
  • Bacteremia / mortality
  • Bacteremia / physiopathology*
  • Child
  • Child, Preschool
  • Colistin
  • Diabetes Complications
  • Diabetes Mellitus
  • Drug Resistance, Bacterial
  • Female
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • Intensive Care Units
  • Lebanon
  • Logistic Models
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Minocycline / analogs & derivatives
  • Mortality
  • Prevalence
  • Respiration, Artificial
  • Retrospective Studies
  • Risk Factors
  • Shock, Septic
  • Steroids / administration & dosage
  • Tigecycline
  • Treatment Outcome*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Steroids
  • Tigecycline
  • Minocycline
  • Colistin